# Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers

> **NCT04083170** · PHASE2 · TERMINATED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 1 (actual)

## Conditions studied

- Acute Erythroid Leukemia
- Acute Lymphoblastic Leukemia
- Acute Megakaryoblastic Leukemia
- Acute Myeloid Leukemia
- Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Hematopoietic and Lymphoid Cell Neoplasm
- HIV Infection
- Myelodysplastic Syndrome
- Myelodysplastic Syndrome With Excess Blasts
- Non-Hodgkin Lymphoma
- Refractory Anemia

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Thiotepa
- **RADIATION:** Total-Body Irradiation
- **PROCEDURE:** Umbilical Cord Blood Transplantation
- **BIOLOGICAL:** Dilanubicel

## Key facts

- **NCT ID:** NCT04083170
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-10-06
- **Primary completion:** 2022-11-11
- **Final completion:** 2022-11-30
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** The federal funding period ended. The study was originally intended to be multi-site but was only conducted at the lead site. Due to the rarity of the subject population \& smaller # of enrolling sites, we were not able to reach accrual goals.
- **Last updated:** 2025-01-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04083170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04083170, "Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04083170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*